Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Xenon(XENE) Newsfilter·2025-04-04 12:30Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficacy of azetukalner in FOS seizure sub-typesPatient survey findings on mental health and comorbidity burdens of FOS VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical co ...